<p>KMG Fiduciary Partners LLC 在最近向证券交易委员会的披露中表示，在第三季度将其在礼来公司的股份增加了 5.5%。该机构投资者在此期间购买了 1,659 股后，持有该公司 31,661 股股票。礼来公司大约占 KMG Fiduciary Partners LLC 投资组合的 1.6%，使其成为该投资者第 11 大持仓。KMG Fiduciary Partners LLC 在礼来公司的持股在最近的报告期末价值为 24,157,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>3 家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他几家对冲基金最近也买卖了 LLY 的股票。Brighton Jones LLC 在第四季度将其在礼来公司的持仓增加了 22.0%。Brighton Jones LLC 现在拥有 9,597 股该公司股票，价值 7,409,000 美元，此前在上个季度又购买了 1,730 股。Revolve Wealth Partners LLC 在第四季度将其在礼来公司的股份增加了 2.8%。Revolve Wealth Partners LLC 现在拥有 1,471 股该公司股票，价值 1,136,000 美元，此前在上个季度又购买了 40 股。Sax Wealth Advisors LLC 在第一季度将其在礼来公司的持股增加了 63.9%。Sax Wealth Advisors LLC 现在拥有 603 股该公司股票，价值 498,000 美元，此前在上个季度又购买了 235 股。AIMZ Investment Advisors LLC 在第一季度将其在礼来公司的持股增加了 16.1%。AIMZ Investment Advisors LLC 现在拥有 584 股该公司股票，价值 483,000 美元，此前在上个季度又购买了 81 股。最后，Enterprise Financial Services Corp 在第一季度将其在礼来公司的持仓增加了 1.2%。Enterprise Financial Services Corp 现在拥有 1,822 股该公司股票，价值 1,505,000 美元，此前在上个季度又购买了 22 股。82.53% 的股票由机构投资者持有。</p>
<h2>影响礼来公司的关键消息</h2>
<p>以下是本周影响礼来公司的关键新闻：</p>
<ul>
<li>积极情绪：晚期试验胜利——礼来的口服 GLP-1 药物 orforglipron 在 ATTAIN-MAINTAIN III 期试验中达到了主要和所有关键次要终点，显示从 Wegovy 或 Zepbound 转换的患者几乎保持了所有之前的体重减轻；礼来已向 FDA 提交了 orforglipron 用于肥胖症的申请。PR Newswire：礼来的 orforglipron 帮助人们维持体重减轻</li>
<li>积极情绪：项目势头和监管进展——中外药业和其他发布强调了积极的 III 期顶线结果以及礼来对 orforglipron 的 FDA 申请，强化了该公司在口服 GLP-1 领域的领导地位。如果获得批准，这将提高快速商业化的前景。TipRanks：中外药业强调积极的 III 期结果</li>
<li>积极情绪：分析师升级和上行预测——美国银行和其他机构指出改善的质量指标并预测实质性上行（美国银行提到新的口服肥胖疗法可能带来数十亿美元的销售），同时大和证券对 LLY 进行了升级——所有这些都支持更高的估值。Benzinga：美国银行看到股票上行空间 American Banking News：大和证券升级</li>
<li>中性情绪：管道深度——礼来将 eloralintide 推进到 III 期，增强了其肥胖/糖尿病管道，超越了 orforglipron；这对长期增长具有战略意义，但不是立即的收入驱动因素。TipRanks：礼来将 eloralintide 推进到 III 期</li>
<li>中性情绪：品牌/营销举措——礼来的消费者宣传（例如，奥运会合作）支持新疗法的认知，但对短期财务影响不明确。MM&amp;M：礼来推出了以美国队为主题的视频</li>
<li>消极情绪：加拿大的价格压力——路透社报道，礼来在加拿大将 Mounjaro 和 Zepbound 的价格削减了约 20% 或更多，这可能会压缩利润率或减少在面临更严格定价/监管审查的市场中每个处方的实际收入。路透社：礼来在加拿大降低糖尿病和减肥药物的价格</li>
</ul>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
<p>LLY 一直是多份研究分析报告的主题。汇丰全球研究在 8 月 27 日的研究报告中将礼来公司的股票评级从 “适度卖出” 上调至 “持有”。中金公司在 11 月 13 日的报告中将礼来公司的目标价从 801.00 美元上调至 1,060.00 美元，并给予该公司 “中性” 评级。摩根大通在 11 月 18 日的研究报告中将礼来公司的目标价从 1,050.00 美元上调至 1,150.00 美元，并给予该股票 “增持” 评级。Loop Capital 在 11 月 10 日的研究报告中对礼来公司设定了 950.00 美元的目标价。最后，大和证券在 12 月 16 日的研究报告中将礼来公司的评级从 “持有” 上调至 “强烈买入”。四位股票研究分析师对该股票给予了强烈买入评级，十七位给予了买入评级，五位给予了持有评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，共识目标价为 1,155.36 美元。</p>
<p><strong>获取我们关于礼来公司的最新研究报告</strong></p>
<h2>礼来公司股票上涨 1.4%</h2>
<ul>
<li>黄金交叉警报：3 只具有重大上行潜力的股票</li>
</ul>
<p>LLY 的股票在周一开盘价为 1,071.35 美元。该公司的市值为 1.01 万亿美元，市盈率为 52.41，市盈增长比率为 1.34，贝塔值为 0.37。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 1,111.99 美元。该股票的 50 日移动平均价格为 960.76 美元，200 日移动平均价格为 831.36 美元。公司的流动比率为 1.55，速动比率为 1.24，债务与股本比率为 1.71。</p>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日（星期四）发布了季度财报。该公司报告本季度每股收益为 7.02 美元，超出市场共识预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的股本回报率为 109.52%，净利润率为 30.99%。该公司本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。去年同期，该公司每股收益为 1.18 美元。该公司的季度收入同比增长 53.9%。礼来公司已将 2025 财年的每股收益指导设定在 23.000-23.700 美元。分析师平均预计礼来公司今年的每股收益为 23.48 美元。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近宣布了季度股息，将于 3 月 10 日（星期二）支付。记录在案的股东将在 2 月 13 日（星期五）获得 1.73 美元的股息。这比礼来公司之前的季度股息 1.50 美元有所增加。除息日期为 2 月 13 日（星期五）。这相当于年化股息为 6.92 美元，股息收益率为 0.6%。礼来公司的股息支付比率目前为 29.35%。</p>
<h2>礼来公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司（NYSE: LLY）是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和治疗方案，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务和商业活动，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过礼来公司</li>
<li>我不应该把这个发给你</li>
<li>华尔街股票挑选者评选 2026 年第一股票</li>
<li>美国结束更新</li>
<li>他们嘲笑 30 美元，但不会嘲笑 70 美元。</li>
<li>100 万美元在退休后能维持多久？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>KMG Fiduciary Partners LLC 在第三季度将其在礼来的股份增加了 5.5%，额外购买了 1,659 股。这使得礼来成为 KMG 投资组合中第 11 大持仓，价值为 24,157,000 美元。其他机构投资者也调整了他们在礼来的持股。由于成功的试验和监管进展，该公司正经历积极的市场情绪，尽管在加拿大面临价格压力</p>

<p>KMG Fiduciary Partners LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.5% during the third quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 31,661 shares of the company's stock after buying an additional 1,659 shares during the period. Eli Lilly and Company makes up approximately 1.6% of KMG Fiduciary Partners LLC's investment portfolio, making the stock its 11th largest position. KMG Fiduciary Partners LLC's holdings in Eli Lilly and Company were worth $24,157,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>KMG Fiduciary Partners LLC 在最近向证券交易委员会的披露中表示，在第三季度将其在礼来公司的股份增加了 5.5%。该机构投资者在此期间购买了 1,659 股后，持有该公司 31,661 股股票。礼来公司大约占 KMG Fiduciary Partners LLC 投资组合的 1.6%，使其成为该投资者第 11 大持仓。KMG Fiduciary Partners LLC 在礼来公司的持股在最近的报告期末价值为 24,157,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>Several other hedge funds have also recently bought and sold shares of LLY. Brighton Jones LLC raised its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Sax Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company by 63.9% during the 1st quarter. Sax Wealth Advisors LLC now owns 603 shares of the company's stock worth $498,000 after buying an additional 235 shares in the last quarter. AIMZ Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 16.1% during the 1st quarter. AIMZ Investment Advisors LLC now owns 584 shares of the company's stock worth $483,000 after buying an additional 81 shares in the last quarter. Finally, Enterprise Financial Services Corp lifted its position in shares of Eli Lilly and Company by 1.2% during the 1st quarter. Enterprise Financial Services Corp now owns 1,822 shares of the company's stock worth $1,505,000 after buying an additional 22 shares during the last quarter. 82.53% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也买卖了 LLY 的股票。Brighton Jones LLC 在第四季度将其在礼来公司的持仓增加了 22.0%。Brighton Jones LLC 现在拥有 9,597 股该公司股票，价值 7,409,000 美元，此前在上个季度又购买了 1,730 股。Revolve Wealth Partners LLC 在第四季度将其在礼来公司的股份增加了 2.8%。Revolve Wealth Partners LLC 现在拥有 1,471 股该公司股票，价值 1,136,000 美元，此前在上个季度又购买了 40 股。Sax Wealth Advisors LLC 在第一季度将其在礼来公司的持股增加了 63.9%。Sax Wealth Advisors LLC 现在拥有 603 股该公司股票，价值 498,000 美元，此前在上个季度又购买了 235 股。AIMZ Investment Advisors LLC 在第一季度将其在礼来公司的持股增加了 16.1%。AIMZ Investment Advisors LLC 现在拥有 584 股该公司股票，价值 483,000 美元，此前在上个季度又购买了 81 股。最后，Enterprise Financial Services Corp 在第一季度将其在礼来公司的持仓增加了 1.2%。Enterprise Financial Services Corp 现在拥有 1,822 股该公司股票，价值 1,505,000 美元，此前在上个季度又购买了 22 股。82.53% 的股票由机构投资者持有。</p>
</div><h2>Key Stores Impacting Eli Lilly and Company</h2>
<div class="lb-trans"><h2>影响礼来公司的关键消息</h2>
</div><p>Here are the key news stories impacting Eli Lilly and Company this week:</p>
<div class="lb-trans"><p>以下是本周影响礼来公司的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Late‑stage trial win — Lilly’s oral GLP‑1 pill orforglipron met the primary and all key secondary endpoints in the ATTAIN‑MAINTAIN Phase 3 trial, showing patients who switched from Wegovy or Zepbound kept essentially all prior weight loss; Lilly has submitted orforglipron to the FDA for obesity. PR Newswire: Lilly's orforglipron helped people maintain weight loss</li>
<li>Positive Sentiment: Program momentum and regulatory progress — Chugai and other releases highlight positive topline Phase 3 results and Lilly’s FDA filing for orforglipron, reinforcing the company’s leadership in oral GLP‑1s. This raises prospects for rapid commercial adoption if approved. TipRanks: Chugai highlights positive Phase 3 results</li>
<li>Positive Sentiment: Analyst upgrades and upside forecasts — Bank of America and other outlets point to improved quality metrics and forecast material upside (BofA cites potential multi‑billion sales for new oral obesity therapies), while Daiwa upgraded LLY — all supportive of higher valuations. Benzinga: BofA sees room for stock upsideAmerican Banking News: Daiwa upgrade</li>
<li>Neutral Sentiment: Pipeline depth — Lilly advanced eloralintide into Phase 3, strengthening its obesity/diabetes pipeline beyond orforglipron; this is strategic for longer‑term growth but not an immediate revenue driver. TipRanks: Lilly advances eloralintide into Phase 3</li>
<li>Neutral Sentiment: Branding/marketing initiatives — Lilly’s consumer outreach (e.g., Olympics tie‑ins) supports awareness for new therapies but has unclear near‑term financial impact. MM&amp;M: Lilly debuts video featuring Team USA</li>
<li>Negative Sentiment: Pricing pressure in Canada — Reuters reported Lilly cut prices of Mounjaro and Zepbound in Canada by ~20% or more, which could compress margins or reduce realized revenue per prescription in markets facing tougher pricing/regulatory scrutiny. Reuters: Lilly cuts price of diabetes, weight-loss drugs in Canada</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：晚期试验胜利——礼来的口服 GLP-1 药物 orforglipron 在 ATTAIN-MAINTAIN III 期试验中达到了主要和所有关键次要终点，显示从 Wegovy 或 Zepbound 转换的患者几乎保持了所有之前的体重减轻；礼来已向 FDA 提交了 orforglipron 用于肥胖症的申请。PR Newswire：礼来的 orforglipron 帮助人们维持体重减轻</li>
<li>积极情绪：项目势头和监管进展——中外药业和其他发布强调了积极的 III 期顶线结果以及礼来对 orforglipron 的 FDA 申请，强化了该公司在口服 GLP-1 领域的领导地位。如果获得批准，这将提高快速商业化的前景。TipRanks：中外药业强调积极的 III 期结果</li>
<li>积极情绪：分析师升级和上行预测——美国银行和其他机构指出改善的质量指标并预测实质性上行（美国银行提到新的口服肥胖疗法可能带来数十亿美元的销售），同时大和证券对 LLY 进行了升级——所有这些都支持更高的估值。Benzinga：美国银行看到股票上行空间 American Banking News：大和证券升级</li>
<li>中性情绪：管道深度——礼来将 eloralintide 推进到 III 期，增强了其肥胖/糖尿病管道，超越了 orforglipron；这对长期增长具有战略意义，但不是立即的收入驱动因素。TipRanks：礼来将 eloralintide 推进到 III 期</li>
<li>中性情绪：品牌/营销举措——礼来的消费者宣传（例如，奥运会合作）支持新疗法的认知，但对短期财务影响不明确。MM&amp;M：礼来推出了以美国队为主题的视频</li>
<li>消极情绪：加拿大的价格压力——路透社报道，礼来在加拿大将 Mounjaro 和 Zepbound 的价格削减了约 20% 或更多，这可能会压缩利润率或减少在面临更严格定价/监管审查的市场中每个处方的实际收入。路透社：礼来在加拿大降低糖尿病和减肥药物的价格</li>
</ul>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
</div><p>LLY has been the topic of a number of research analyst reports. Hsbc Global Res upgraded shares of Eli Lilly and Company from a &#34;moderate sell&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, August 27th. CICC Research raised their price objective on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, November 13th. JPMorgan Chase &amp; Co. boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, November 18th. Loop Capital set a $950.00 target price on Eli Lilly and Company in a research report on Monday, November 10th. Finally, Daiwa America raised Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, December 16th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $1,155.36.</p>
<div class="lb-trans"><p>LLY 一直是多份研究分析报告的主题。汇丰全球研究在 8 月 27 日的研究报告中将礼来公司的股票评级从 “适度卖出” 上调至 “持有”。中金公司在 11 月 13 日的报告中将礼来公司的目标价从 801.00 美元上调至 1,060.00 美元，并给予该公司 “中性” 评级。摩根大通在 11 月 18 日的研究报告中将礼来公司的目标价从 1,050.00 美元上调至 1,150.00 美元，并给予该股票 “增持” 评级。Loop Capital 在 11 月 10 日的研究报告中对礼来公司设定了 950.00 美元的目标价。最后，大和证券在 12 月 16 日的研究报告中将礼来公司的评级从 “持有” 上调至 “强烈买入”。四位股票研究分析师对该股票给予了强烈买入评级，十七位给予了买入评级，五位给予了持有评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，共识目标价为 1,155.36 美元。</p>
</div><p><strong>Get Our Latest Research Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>获取我们关于礼来公司的最新研究报告</strong></p>
</div><h2>Eli Lilly and Company Stock Up 1.4%</h2>
<div class="lb-trans"><h2>礼来公司股票上涨 1.4%</h2>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：3 只具有重大上行潜力的股票</li>
</ul>
</div><p>Shares of LLY opened at $1,071.35 on Monday. The company has a market capitalization of $1.01 trillion, a PE ratio of 52.41, a PEG ratio of 1.34 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The stock's 50-day moving average price is $960.76 and its two-hundred day moving average price is $831.36. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.</p>
<div class="lb-trans"><p>LLY 的股票在周一开盘价为 1,071.35 美元。该公司的市值为 1.01 万亿美元，市盈率为 52.41，市盈增长比率为 1.34，贝塔值为 0.37。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 1,111.99 美元。该股票的 50 日移动平均价格为 960.76 美元，200 日移动平均价格为 831.36 美元。公司的流动比率为 1.55，速动比率为 1.24，债务与股本比率为 1.71。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion during the quarter, compared to analysts' expectations of $16.09 billion. During the same quarter in the prior year, the firm posted $1.18 earnings per share. The business's quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日（星期四）发布了季度财报。该公司报告本季度每股收益为 7.02 美元，超出市场共识预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的股本回报率为 109.52%，净利润率为 30.99%。该公司本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。去年同期，该公司每股收益为 1.18 美元。该公司的季度收入同比增长 53.9%。礼来公司已将 2025 财年的每股收益指导设定在 23.000-23.700 美元。分析师平均预计礼来公司今年的每股收益为 23.48 美元。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's dividend payout ratio is presently 29.35%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，将于 3 月 10 日（星期二）支付。记录在案的股东将在 2 月 13 日（星期五）获得 1.73 美元的股息。这比礼来公司之前的季度股息 1.50 美元有所增加。除息日期为 2 月 13 日（星期五）。这相当于年化股息为 6.92 美元，股息收益率为 0.6%。礼来公司的股息支付比率目前为 29.35%。</p>
</div><h2>Eli Lilly and Company Profile</h2>
<div class="lb-trans"><h2>礼来公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>礼来公司（NYSE: LLY）是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和治疗方案，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务和商业活动，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>I Shouldn't Be Sending You This</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>End of America update</li>
<li>They Laughed at $30. They Won’t Laugh at $70.</li>
<li>How Long Will $1M Last in Retirement?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过礼来公司</li>
<li>我不应该把这个发给你</li>
<li>华尔街股票挑选者评选 2026 年第一股票</li>
<li>美国结束更新</li>
<li>他们嘲笑 30 美元，但不会嘲笑 70 美元。</li>
<li>100 万美元在退休后能维持多久？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

KMG Fiduciary Partners LLC 购买了 1,659 股礼来公司（Eli Lilly）的股票$LLY